Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CX516 in Alzheimer's Disease
NCT00001662Phase 2Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Dec 1996
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing CX516 Arm with Placebo Arm (2 arms). Primary endpoint: Drug-induced alterations in intellectual function at 12 weeks. Started Dec 1996; status: completed.
02
Drugs
cx516
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00001662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001662.